M&A Deal Summary

Luminex Acquires Nanosphere

On May 16, 2016, Luminex acquired life science company Nanosphere for 58M USD

Acquisition Highlights
  • This is Luminex’s 3rd transaction in the Life Science sector.
  • This is Luminex’s 2nd largest (disclosed) transaction.
  • This is Luminex’s 3rd transaction in the United States.
  • This is Luminex’s 1st transaction in Illinois.

M&A Deal Summary
Date 2016-05-16
Target Nanosphere
Sector Life Science
Buyer(s) Luminex
Deal Type Add-on Acquisition
Deal Value 58M USD
Advisor(s) Jefferies (Financial)
Seyfarth Shaw (Legal)

Target

Nanosphere

Northbrook, Illinois, United States
Nanosphere, Inc. is a provider of molecular microbiology and molecular diagnostic market.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Luminex

Austin, Texas, United States
Category Company
Founded 1995
Sector Medical Products
Employees1,325
Revenue 417M USD (2020)
DESCRIPTION

Luminex is a developer, manufacturer and marketer of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex was founded in 1995 and is based in Austin, Texas.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 3 of 3
State (Illinois) 1 of 1
Country (United States) 3 of 3
Year (2016) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-07-09 GenturaDx

Austin, Texas, United States

GenturaDx, Inc. is a molecular diagnostic company focused on developing and manufacturing high-performance molecular diagnostic products that are both affordable and practical for any laboratory.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-18 Merck KGaA - Flow Cytometry Portfolio

Darmstadt, Germany

Merck KGaA - Flow Cytometry Portfolio includes Amnis, the market-leading family of imaging flow cytometry products for cell-based analysis, as well as their Guava portfolio of products, which are economical, high-performance systems based on microcapillary technologies.

Buy €63M
Mergr

Product

Company

Legal